Prescryptive Health, Lilly partner on first-to-market value-based program to stabilize insulin pricing
The new financial model aims to provide price transparency while encouraging medication adherence.
The newly launched program provides a personalized approach using pharmacists to reduce total health care costs related to diabetes.
Partnership will utilize digital engagement strategies and research to create a robust clinical intervention that is meaningful and engaging to the target population.
The provider brings its omnichannel healthcare approach to chronic condition management and sets the standard for the future of primary care.
Dexcom G6 users can see glucose levels and trends at a glance, even while working out.
Partners offer app compatibility with Tempo Pen and Tempo Smart Button to help streamline diabetes management.
The two companies will collaborate to create a new version of the BlueStar insulin management solution that integrates insulin data for Lilly insulins.
This year, it is expected to exceed $742M, growing at an average CAGR of 50% annually.
The device uses thermographic monitoring of a patient's feet to identify early onset of diabetic foot ulcers, which can lead to limb loss if not detected early.
The partnership will provide personalized diabetes support with the protection of life insurance and the potential to earn up to 25% in premium savings.